Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 94

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 94
---
 may make to its orphan drug regulations and policies, our business could be adversely impacted.

The issuance of shares of our Common Stock upon conversion or exercise of our outstanding Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Common Warrants and other securities that we may issue in future financing transactions may result in substantial dilution to our stockholders.

As of August 19, 2025,
the Company currently has outstanding (i) 1,429 shares of Series A Preferred Stock with a conversion value of approximately $1.4
million, convertible into shares of Common Stock at a conversion rate of the stated value thereof divided by a current effective
conversion price of $1.76; (ii) 7 shares of Series C Preferred Stock with a stated value of approximately $7,000, convertible into
shares of Common Stock at a conversion rate of the stated value thereof divided by a conversion price ranging from $5.00 to $1.76
(iii) Series A Warrants to purchase 306 shares of Common Stock at an exercise price of $2,780.00 per share; (iv) Series C Warrants
to purchase 4,088 shares of Common Stock at an exercise price of $0.80; (v) December 2024 and January 2025 Common Warrants to
purchase an aggregate of 12,396 shares of Common Stock at an exercise price ranging from $112.20 to $116.40, (vi) February 2025
Common Warrants to purchase an aggregate of 127,551 shares of Common Stock at an exercise price of $39.20, (vii) Pre-Funded Warrants
to purchase an aggregate of 10,787 shares of Common Stock at an exercise price of $0.002, (ix) Public Warrants and Private Placement
Warrants to purchase an aggregate of 4,596 shares of Common Stock at an exercise price of $23,000.00 per share and (x) 10,000 shares
of Series D Preferred Stock with a conversion value of approximately $10 million, convertible into shares of Common Stock at a
conversion rate of the stated value thereof divided by a current effective conversion price of $15.60.

<div align='center'>41</div>

Although each of the conversion price of most of the Preferred Shares
and the exercise prices of the December 2024 Common Warrants, January 2025 Common Warrants, Series A Warrants and